LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
04
01
2024
accepted:
30
08
2024
revised:
28
06
2024
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1-35.0). Patients (N = 248) had received median 4 prior LOT (range, 2-13) at enrollment. 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI, 26.1-38.0), median progression-free survival (PFS) was 4.6 months (95% CI, 3.9-5.6) and median overall survival was 13.8 months (95% CI, 10.8-17.0). 152 patients (61.3%) had subsequent LOTs with 134 unique regimens, of which 78 were used in first subsequent LOT. Median PFS2 (from start of study through first subsequent LOT) was 10.8 months (95% CI, 8.4-13.0). 158 patients died on study, 67.7% due to progressive disease. Additional subgroup analyses and long-term safety summaries are reported. The high number of RWCP treatment regimens utilized and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.
Identifiants
pubmed: 39322709
doi: 10.1038/s41375-024-02404-6
pii: 10.1038/s41375-024-02404-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Rodriguez-Otero P, San-Miguel JF. Cellular therapy for multiple myeloma: what’s now and what’s next. Hematol Am Soc Hematol Educ Program. 2022;2022:180–9.
doi: 10.1182/hematology.2022000396
de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers. 2022;15:155.
doi: 10.3390/cancers15010155
pubmed: 36612152
pmcid: 9818178
Rodríguez-Lobato LG, Pereira A, Fernández de Larrea C, Cibeira MT, Tovar N, Jiménez-Segura R, et al. Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period. Br J Haematol. 2022;196:649–59.
doi: 10.1111/bjh.17888
pubmed: 34622447
Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, et al. Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers. 2023;15:2160.
doi: 10.3390/cancers15072160
pubmed: 37046821
pmcid: 10093129
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086–107.
doi: 10.1002/ajh.26590
pubmed: 35560063
pmcid: 9387011
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252–64.
doi: 10.1111/bjh.14213
pubmed: 27411022
pmcid: 5096152
van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. Hematol Am Soc Hematol Educ Program. 2020;2020:248–58.
doi: 10.1182/hematology.2020000109
Moreau PW, K. De Stefano, V et al. Updated Results from LocoMMotion: A Prospective, Nonintervational, Multinational Study of Real-Life Current Standards of Care in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma. In: 19th International Myeloma Society (IMS) Annual Meeting. Los Angeles, CA, USA: IMS; 2022.
Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29:2416–7.
doi: 10.1038/leu.2015.290
pubmed: 26487274
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.
doi: 10.1016/S1470-2045(16)30206-6
pubmed: 27511158
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5.
doi: 10.1182/blood-2010-10-299487
pubmed: 21292775
pmcid: 3710442
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36:1371–6.
doi: 10.1038/s41375-022-01531-2
pubmed: 35332278
pmcid: 9061296
Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355–61.
doi: 10.1634/theoncologist.2016-0104
pubmed: 27486203
pmcid: 5189616
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.
doi: 10.1038/s41375-019-0435-7
pubmed: 30858549
pmcid: 6820050
Mateos MV, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2023;108:2192–204.
doi: 10.3324/haematol.2022.280482
pubmed: 36546453
Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and/or refractory multiple myeloma. Adv Ther. 2023;40:2412–25.
doi: 10.1007/s12325-023-02480-7
pubmed: 36961654
pmcid: 10129954
Celgene Corporation, a Bristol Myers Squibb Company: ABECMA
Janssen Biotech, Inc and Legend Biotech: CARVYKTI
Janssen Biotech, Inc: TECVAYLI
Bristol Myers Squibb Pharma: ABECMA
Janssen Biotech, Inc and Legend Biotech: CARVYKTI
Janssen Biotech, Inc: TECVAYLI